GLP-1 receptor agonist
Dulaglutide
Sold as Trulicity — once weekly, subcutaneous injection.
▲ Not a weight-loss medication
This brand is licensed for type 2 diabetes, not for weight management, so there is no weight-loss trial endpoint to quote here. Its manufacturer says so directly on the brand site.
What it is licensed for
Lilly states Trulicity “is for adults and children 10 years of age and older with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose),” and additionally “in adults with type 2 diabetes to reduce the risk of major cardiovascular events… such as death, heart attack, or stroke in people who have heart disease or multiple cardiovascular risk factors.”
Weight change is a documented effect of this drug class, but that is not the same as being licensed for it. The approved indication is what determines whether a prescriber can legitimately write it for weight, whether an insurer will cover it on that basis, and which savings programme applies.
Worth knowing
- Lilly states plainly on the Trulicity site: “Trulicity is not a weight loss drug.” It is included here because it is one of the most widely prescribed GLP-1s and is routinely confused for one.
- Available at 0.75 mg, 1.5 mg, 3 mg and 4.5 mg per 0.5 mL, injected once weekly.
- There is no weight-management indication and therefore no weight endpoint to quote alongside Wegovy, Zepbound or Foundayo.
- A Trulicity Savings Program is referenced on the brand site, but its terms were not stated on the page we checked.
Full indication
Lilly states Trulicity “is for adults and children 10 years of age and older with type 2 diabetes used along with diet and exercise to improve blood sugar (glucose),” and additionally “in adults with type 2 diabetes to reduce the risk of major cardiovascular events… such as death, heart attack, or stroke in people who have heart disease or multiple cardiovascular risk factors.”